Yue-Fang Wang1, Ge Zhang1, Yong-Mei Jiang2, Ju Gao3. 1. Department of Laboratory Medicine, West China University Second Hospital, Sichuan University; Key Laboratory of Birth Defects and Related Diseases of Women and Children, (Sichuan University), Ministry of Education. Chengdu 610041, Sichuan Province, China. 2. Department of Laboratory Medicine, West China University Second Hospital, Sichuan University; Key Laboratory of Birth Defects and Related Diseases of Women and Children, (Sichuan University), Ministry of Education. Chengdu 610041, Sichuan Province, China.E-mail: 505926169@qq.com. 3. Department of Pediatric Hematology, West China University Second Hospital, Sichuan University; Key Laboratory of Birth Defects and Related Diseases of Women and Children, (Sichuan University), Ministry of Education. Chengdu 610041, Sichuan Province, China.E-mail: tree20002005@163.com.
Abstract
OBJECTIVE: To determine whether immune differentiation antigen is related with clinical features and minimal residual disease (MRD) in childhood B-cell precursor acute lymphoblastic leukemia (B-ALL), who were treated with CCCG-ALL-2015 protocol. METHODS: A retrospective analysis was conducted in 132 B-ALL children, Multiparametric flow cytometry was used to analyze the immunophenotypes. The children were divided into 2 groups by MRD>0.1% on d 19 and / or d 46 after chemotherapy. The Wilcoxon rank-sum test and χ2 test were used for the comparison between groups, and P<0.05 was considered statistically significant. RESULTS: CD19 (100%), CD22 (99.3%) and cCD79a (97.9%) were specific markers for patients with B-ALL, the CD13 and CD33 were mainly cross myeloid antigen. The significant differences were found between CD45- and CD45+ in WBC counts when being firstly diagnosed (Z=6.845, P<0.01), risk stratification (χ2=8.260, P<0.05) and prednisone poor responder (χ2=18.420, P<0.01). Significant differences were found between CD10- and CD10+ in age (Z=6.253, P<0.05), risk stratification (χ2=6.699, P<0.05) and MRD (χ2=4.951, P<0.05). CONCLUSION: In CCCG-ALL-2015 protocol, the CD10 relates with the early MRD, suggesting a better prognosis, and reducing the adverse effects of CD20 and cross myeloid antigen on prognosis.
OBJECTIVE: To determine whether immune differentiation antigen is related with clinical features and minimal residual disease (MRD) in childhood B-cell precursor acute lymphoblastic leukemia (B-ALL), who were treated with CCCG-ALL-2015 protocol. METHODS: A retrospective analysis was conducted in 132 B-ALL children, Multiparametric flow cytometry was used to analyze the immunophenotypes. The children were divided into 2 groups by MRD>0.1% on d 19 and / or d 46 after chemotherapy. The Wilcoxon rank-sum test and χ2 test were used for the comparison between groups, and P<0.05 was considered statistically significant. RESULTS:CD19 (100%), CD22 (99.3%) and cCD79a (97.9%) were specific markers for patients with B-ALL, the CD13 and CD33 were mainly cross myeloid antigen. The significant differences were found between CD45- and CD45+ in WBC counts when being firstly diagnosed (Z=6.845, P<0.01), risk stratification (χ2=8.260, P<0.05) and prednisone poor responder (χ2=18.420, P<0.01). Significant differences were found between CD10- and CD10+ in age (Z=6.253, P<0.05), risk stratification (χ2=6.699, P<0.05) and MRD (χ2=4.951, P<0.05). CONCLUSION: In CCCG-ALL-2015 protocol, the CD10 relates with the early MRD, suggesting a better prognosis, and reducing the adverse effects of CD20 and cross myeloid antigen on prognosis.